Vermillion, Inc. (Nasdaq: VRMLD), a molecular diagnostics company, presented data from several studies demonstrating the benefits of the Company's ovarian cancer protein biomarker panel. The data suggest that use of Vermillion's biomarkers could help better identify women with ovarian cancer, as well as improve the detection of early-stage disease.